Reimbursed Care Access in Montserrat

Currently classified as a strictly controlled substance under Montserrat's drug control framework, with no authorised medical use or reimbursement program outside of approved clinical research or individually issued licences under the Drugs (Prevention of Misuse) regime. Clinical or research access would require explicit licensing under the territory's regulations; there is no public reimbursement or routine clinical pathway for psilocybin therapy. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public reimbursement scheme for MDMA‑assisted therapy in Montserrat and possession, supply or importation without explicit licence is an offence under the Drugs (Prevention of Misuse) Act and subsidiary regulations. #

Esketamine (intranasal SPRAVATO®) is not known to be authorised or reimbursed for routine use in Montserrat; the territory’s drug law framework permits medical use of controlled medicines only under the licensing and regulatory provisions established by the Drugs (Prevention of Misuse) Act and its regulations, and any introduction of a branded product such as SPRAVATO® would require formal authorisation/import/licence by Montserrat authorities. There is no public evidence of a Montserrat‑wide reimbursement program or of a territorial medicine regulatory approval listing for SPRAVATO®; as a small British Overseas Territory with limited hospital/pharmacy infrastructure, novel centrally regulated psychiatric drugs are typically accessed only via authorised importation for clinical use or under special licence. For background on how Montserrat’s regulations permit medical supply under licence and exclude certain Schedule 4 drugs from routine medical prescription without licence, see the judicial analysis of the territory’s Drugs (Prevention of Misuse) framework. # #.

Ketamine as an anaesthetic and analgesic is a recognised medical agent and—where medically indicated—may be supplied and used within Montserrat’s healthcare settings under the Drugs (Prevention of Misuse) regulatory regime (i.e., supply/possession by authorised medical practitioners and institutions is permitted under the Regulations and licensing provisions). The territory’s small public health system (Glendon Hospital / district clinics) provides acute and anaesthetic care where controlled anaesthetics including ketamine are used in standard clinical practice; such medical use is governed by the Drugs (Prevention of Misuse) Act and subsidiary regulations which allow certain scheduled drugs to be produced, supplied or possessed for medical purposes by listed professionals or under licence. There is no public evidence of a territorial, reimbursed program for ketamine therapy for psychiatric indications (e.g., treatment‑resistant depression) similar to national reimbursement programmes in larger jurisdictions; psychiatric use—if provided—would generally be clinician‑directed, likely paid privately or arranged case‑by‑case, and would require local clinical governance and import/licence arrangements for any specialised preparations. For legislative context and the regulatory licence route for medical supply, see the territory legal commentary. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public reimbursement or clinical access pathway for DMT in Montserrat. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no sanctioned medical or reimbursed access pathway for 5‑MeO‑DMT in Montserrat. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no regulated, reimbursed access to ibogaine therapy in Montserrat. #

Currently classified as a strictly controlled substance (primarily because key active tryptamines such as DMT are controlled) under Montserrat’s drug laws, with no authorised medical program or public reimbursement. Use or importation of ayahuasca preparations would require explicit licensing for research or individual ministerial licence; otherwise such possession/supply is prohibited. #

Currently classified as a strictly controlled substance under national scheduling laws, with no authorised medical use or reimbursement in Montserrat outside of authorised research licences. Peyote/mescaline preparations are not part of any public therapeutic programme on the island. #

Currently classified as a strictly controlled substance under national drug scheduling laws (phenethylamine psychedelics are treated as controlled), with no authorised medical use and no reimbursement—access is limited to properly authorised clinical research licences only. #